Skip to main content
Premium Trial:

Request an Annual Quote

Debiopharm, Quartz Bio Collaborate on NGS, Biomarker Data Analyses

NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.

Quartz Bio, a clinical bioinformatics firm spun out by Merck Serono last September, will provide its expertise in computational analyses and biomarker discovery to Debiopharm’s projects, which are anticipated to range from next-generation sequencing and clinical biomarker data analyses.

"Debiopharm's pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of precision medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients," Jerome Wojcik, CEO of Swizerland-based Quartz Bio, said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.